Cleveland Clinic, Dyania Health Partner For Research Studies

Cleveland Clinic is partnering with Dyania Health, an AI-enabled healthcare data company, to roll out Dyania’s Synapsis AI platform across its clinical research enterprise.

Synapsis AI uses medically trained large language models to extract and interpret information from clinical notes, medical records, imaging, and pathology. It combines this data with other variables, such as organ function or patient age, to generate precise medical insights.

The collaboration builds on pilot programs in cardiology and oncology, as well as a successful validation study in neurology. The goal is to speed up and scale patient identification for clinical trials, easing enrollment bottlenecks and expanding access to therapies.

In one pilot, Cleveland Clinic researchers compared Synapsis AI to two experienced nurses during screening for a melanoma trial. The AI identified an eligible patient in 2.5 minutes with 96% accuracy, compared to 95% accuracy in 427 minutes by a melanoma-specialized nurse and 88% accuracy in 540 minutes by an oncology research nurse. The platform has also been used with the Heart, Vascular and Thoracic Institute to screen participants for the DepleTTR-CM Phase 3 trial in transthyretin amyloid cardiomyopathy, a rare and fatal heart condition.

“Through our collaboration with Dyania Health, we are leveraging their AI platform to accelerate clinical trials and create a research infrastructure that benefits both investigators and patients,” said Dr. Lara Jehi, Cleveland Clinic’s chief research information officer. “Its ability to quickly analyze complex data and identify potential candidates complements the expertise of healthcare professionals and can improve access to care, particularly for underrepresented populations.”

Dyania Health founder and CEO Eirini Schlosser added, “By scaling Synapsis AI across Cleveland Clinic, we are transforming clinical research into something more proactive and inclusive. Eligible patients are surfaced in real time, investigators gain greater confidence in their cohorts, and discoveries move from concept to care faster.”

This collaboration reflects a broader trend in AI-driven healthcare innovation. Earlier this month, Cleveland Clinic-led research showed that a bundled, technology-enabled intervention system—delivering AI-driven insights and personalized lifestyle recommendations—improved glycemic control in adults with type 2 diabetes. Results published in the New England Journal of Medicine Catalyst revealed that 71% of participants achieved an A1C of 6.5% with fewer medications.

However, Cleveland Clinic and Amwell’s 2024 survey found that despite interest in virtual care solutions, many patients remain cautious about AI in diagnosis. The same study showed that virtual second opinion (VSO) services significantly increased patients’ likelihood of seeking follow-up care, with 89% expressing strong interest in VSOs when facing major medical decisions.

For Dyania, the Cleveland Clinic rollout follows a $10 million Series A funding round in 2024, led by HealthX, TechSquare, and Cleveland Clinic Ventures, with support from existing investors. The financing has been used to further advance Synapsis AI and its applications in clinical research.